|
WO2014089004A1
|
|
Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
|
|
MX2012004383A
|
|
Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors.
|
|
US2009291967A1
|
|
Small molecule modulators of cell adhesion
|
|
WO2009100367A2
|
|
Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
|
|
US2009131306A1
|
|
Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
|
|
US2008255168A1
|
|
Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
|
|
US2008194467A1
|
|
Cancer treatment methods using cadherin antagonists in combination with anticancer agents
|
|
CN101068549A
|
|
Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
|
|
US2005222037A1
|
|
Compounds and methods for modulating VE-cadherin-mediated function
|
|
US2005215482A1
|
|
Compounds and methods for modulating OB-cadherin-mediated function
|
|
US2005203025A1
|
|
Compounds and methods for modulating nonclassical cadherin-mediated functions
|
|
US2005129676A1
|
|
Compounds and methods for modulating functions of classical cadherins
|
|
AU2003298475A1
|
|
Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
|
|
US2004254099A1
|
|
Compounds and methods for modulating beta-catenin mediated gene expression
|
|
US7122623B2
|
|
Compounds and methods for modulating cell adhesion
|
|
AU2922802A
|
|
Methods for diagnosing and evaluating cancer
|
|
WO0153331A2
|
|
Peptidomimetic modulators of cell adhesion
|
|
WO0059939A1
|
|
COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
|
|
US6638911B1
|
|
Compounds and methods for modulating desmosomal cadherin-mediated functions
|
|
US6797807B1
|
|
Compounds and methods for cancer therapy
|
